Skip to main content
SpringerLink
Log in

Prevention and treatment of contrast-associated nephropathy in interventional cardiology

  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Contrast-induced nephropathy (CIN) is a common complication after diagnostic and therapeutic cardiovascular procedures that is associated with significant mortality and morbidity. CIN is highly prevalent in patients with well-known risk factors, including older age, chronic renal insufficiency, congestive heart failure, and diabetes. Thus far, no strategies have been shown to be effective in preventing CIN beyond thorough patient selection, minimizing the amount of contrast agent, and meticulous hydration of the patient. The role of various drugs in preventing CIN is still controversial and warrants future studies. Despite the remaining uncertainty regarding the degree of nephrotoxicity produced by various contrast agents, nonionic low-osmolar contrast media may be preferred in patients at high risk for CIN.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Hou SH, Bushinsky DA, Wish JB, et al.: Hospital-acquired renal insufficiency: a prospective study. Am J Med 1983, 74:243–248.

    Article  PubMed  CAS  Google Scholar 

  2. Gruberg L, Mintz GS, Mehran R, et al.: The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000, 36:1542–1548.

    Article  PubMed  CAS  Google Scholar 

  3. McCullough PA, Wolyn R, Rocher LL, et al.: Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997, 103:368–375.

    Article  PubMed  CAS  Google Scholar 

  4. Rihal CS, Textor SC, Grill DE, et al.: Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002, 105:2259–2264.

    Article  PubMed  Google Scholar 

  5. Solomon R, Deray G; Consensus Panel for CIN: How to prevent contrast-induced nephropathy and manage risk patients: practical recommendations. Kidney Int Suppl 2006, Apr:S51–S53.

  6. Goldenberg I, Matetzky S: Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ 2005, 172:1461–1471.

    PubMed  Google Scholar 

  7. Nikolsky E, Mehran R, Lasic Z, et al.: Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney Int 2005, 67:706–713.

    Article  PubMed  Google Scholar 

  8. Hall KA, Wong RW, Hunter GC, et al.: Contrast-induced nephrotoxicity: the effects of vasodilator therapy. J Surg Res 1992, 53:317–320.

    Article  PubMed  CAS  Google Scholar 

  9. Nikolsky E, Mehran R, Turcot D, et al.: Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol 2004, 94:300–305.

    Article  PubMed  Google Scholar 

  10. Mehran R, Aymong ED, Nikolsky E, et al.: A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004, 44:1393–1399.

    PubMed  Google Scholar 

  11. Persson PB, Tepel M: Contrast medium-induced nephropathy: the pathophysiology. Kidney Int Suppl 2006, Apr:S8–S10.

    Google Scholar 

  12. Tumlin JA, Wang A, Murray PT, Mathur VS: Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J 2002, 143:894–903.

    Article  PubMed  CAS  Google Scholar 

  13. Russo D, Minutolo R, Cianciaruso B, et al.: Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. J Am Soc Nephrol 1995, 6:1451–1458.

    PubMed  CAS  Google Scholar 

  14. Ribeiro L, de Assuncao e Silva F, Kurihara RS, et al.: Evaluation of the nitric oxide production in rat renal artery smooth muscle cells culture exposed to radiocontrast agents. Kidney Int 2004, 65:589–596.

    Article  PubMed  CAS  Google Scholar 

  15. Mueller C: Prevention of contrast-induced nephropathy with volume supplementation. Kidney Int Suppl 2006, Apr:S16–S19.

    Article  Google Scholar 

  16. Solomon R, Werner C, Mann D, et al.: Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994, 331:1416–1420.

    Article  PubMed  CAS  Google Scholar 

  17. Mueller C, Buerkle G, Buettner HJ, et al.: Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002, 162:329–336.

    Article  PubMed  CAS  Google Scholar 

  18. Taylor AJ, Hotchkiss D, Morse RW, McCabe J: PREPARED: Preparation for Angiography in Renal Dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest 1998, 114:1570–1574.

    Article  PubMed  CAS  Google Scholar 

  19. Trivedi HS, Moore H, Nasr S, et al.: A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract 2003, 93:C29–C34.

    Article  PubMed  CAS  Google Scholar 

  20. Bader BD, Berger ED, Heede MB, et al.: What is the best hydration regimen to prevent contrast media-induced nephrotoxicity? Clin Nephrol 2004, 62:1–7.

    PubMed  CAS  Google Scholar 

  21. Krasuski RA, Beard BM, Geoghagan JD, et al.: Optimal timing of hydration to erase contrast-associated nephropathy: the OTHER CAN study. J Invasive Cardiol 2003, 15:699–702.

    PubMed  Google Scholar 

  22. Stacul F, Adam A, Becker CR, et al.: Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol 2006, 98:59K–77K.

    Article  PubMed  CAS  Google Scholar 

  23. Merten GJ, Burgess WP, Gray LV, et al.: Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004, 291:2328–2334.

    Article  PubMed  CAS  Google Scholar 

  24. Briguori C, Airoldi F, D’Andrea D, et al.: Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation 2007, 115:1211–1217.

    PubMed  CAS  Google Scholar 

  25. Ozcan EE, Guneri S, Akdeniz B, et al.: Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial. Am Heart J 2007, 154:539–544.

    Article  PubMed  CAS  Google Scholar 

  26. Brar SS, Shen AY, Jorgensen MB, et al.: Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA 2008, 300:1038–1046.

    Article  PubMed  CAS  Google Scholar 

  27. Adolph E, Holdt-Lehmann B, Chatterjee T, et al.: Renal Insufficiency Following Radiocontrast Exposure Trial (REINFORCE): a randomized comparison of sodium bicarbonate versus sodium chloride hydration for the prevention of contrast-induced nephropathy. Coron Artery Dis 2008, 19:413–419.

    PubMed  Google Scholar 

  28. Maioli M, Toso A, Leoncini M, et al.: Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. J Am Coll Cardiol 2008, 52:599–604.

    Article  PubMed  CAS  Google Scholar 

  29. From AM, Bartholmai BJ, Williams AW, et al.: Sodium bicarbonate is associated with an increased incidence of contrast nephropathy: a retrospective cohort study of 7977 patients at mayo clinic. Clin J Am Soc Nephrol 2008, 3:10–18.

    Article  PubMed  CAS  Google Scholar 

  30. Tepel M, van der Giet M, Schwarzfeld C, et al.: Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000, 343:180–184.

    Article  PubMed  CAS  Google Scholar 

  31. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW: Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002, 89:356–358.

    Article  PubMed  CAS  Google Scholar 

  32. Webb JG, Pate GE, Humphries KH, et al.: A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. Am Heart J 2004, 148:422–429.

    Article  PubMed  CAS  Google Scholar 

  33. Kelly AM, Dwamena B, Cronin P, et al.: Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med 2008, 148:284–294.

    PubMed  Google Scholar 

  34. Stone GW, McCullough PA, Tumlin JA, et al.: Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003, 290:2284–2291.

    Article  PubMed  CAS  Google Scholar 

  35. Bagshaw SM, Ghali WA: Theophylline for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Arch Intern Med 2005, 165:1087–1093.

    Article  PubMed  Google Scholar 

  36. Khanal S, Attallah N, Smith DE, et al.: Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med 2005, 118:843–849.

    Article  PubMed  CAS  Google Scholar 

  37. Jo SH, Koo BK, Park JS, et al.: Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial-a randomized controlled study. Am Heart J 2008, 155:499.e1–499.e8.

    Article  Google Scholar 

  38. Kurnik BR, Allgren RL, Genter FC, et al.: Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J Kidney Dis 1998, 31:674–680.

    Article  PubMed  CAS  Google Scholar 

  39. Morikawa S, Sone T, Tsuboi H, et al.: Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide. J Am Coll Cardiol 2009, 53:1040–1046.

    Article  PubMed  CAS  Google Scholar 

  40. Lee PT, Chou KJ, Liu CP, et al.: Renal protection for coronary angiography in advanced renal failure patients by prophylactic hemodialysis. A randomized controlled trial. J Am Coll Cardiol 2007, 50:1015–1020.

    Article  PubMed  Google Scholar 

  41. Marenzi G, Lauri G, Campodonico J, et al.: Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. Am J Med 2006, 119:155–162.

    Article  PubMed  Google Scholar 

  42. Weisz G, Filby SJ, Cohen MG, et al.: Safety and performance of targeted renal therapy: the Be-RITe! Registry. J Endovasc Ther 2009, 16:1–12.

    Article  PubMed  Google Scholar 

  43. Marenzi G, Assanelli E, Campodonico J, et al.: Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality. Ann Intern Med 2009, 150:170–177.

    PubMed  Google Scholar 

  44. Rudnick MR, Goldfarb S, Wexler L, et al.: Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int 1995, 47:254–261.

    Article  PubMed  CAS  Google Scholar 

  45. McCullough PA, Bertrand ME, Brinker JA, Stacul F: A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol 2006, 48:692–699.

    Article  PubMed  CAS  Google Scholar 

  46. Jo SH, Youn TJ, Koo BK, et al.: Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. J Am Coll Cardiol 2006, 48:924–930.

    Article  PubMed  CAS  Google Scholar 

  47. Mehran R, Nikolsky E, Kirtane AJ, et al.: Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic Versus Non-ionic Contrast to Obviate Worsening Nephropathy After Angioplasty in Chronic Renal Failure Patients) study. JACC Cardiovasc Interv 2009, 2:415–421.

    Article  PubMed  Google Scholar 

  48. Solomon RJ, Natarajan MK, Doucet S, et al.: Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation 2007, 115:3189–3196.

    Article  PubMed  Google Scholar 

  49. Wessely R, Koppara T, Kastrati A, et al.: Randomized clinical trial to compare the nephrotoxic effects of iso-osmolar versus low-osmolar contrast medium in patients with impaired renal function undergoing percutaneous coronary intervention: the COntrast media and NephroToxicity following coronary revascularization by angioplaSTy (CONTRAST) Study. Paper presented at SCAI-ACCi2 2008. Chicago, IL; April 1, 2008.

  50. Rudnick MR, Davidson C, Laskey W, et al.: Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) Trial. Am Heart J 2008, 156:776–782.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Data Coordinating & Analysis Center, Cardiovascular Research Foundation, 111 East 59th Street, 11th Floor, New York, NY, 10022, USA

    Roxana Mehran

Authors
  1. Adriano Caixeta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eugenia Nikolsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Roxana Mehran
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roxana Mehran.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Caixeta, A., Nikolsky, E. & Mehran, R. Prevention and treatment of contrast-associated nephropathy in interventional cardiology. Curr Cardiol Rep 11, 377–383 (2009). https://doi.org/10.1007/s11886-009-0052-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11886-009-0052-6

Keywords

Search

Navigation